Page last updated: 2024-11-04

suramin and Dysesthesia

suramin has been researched along with Dysesthesia in 4 studies

Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.

Research Excerpts

ExcerptRelevanceReference
"Ten male patients with onchocerciasis received six weekly infusions of suramin according to the WHO-recommended regimen."9.08Clinical pharmacokinetics of suramin in patients with onchocerciasis. ( Chijioke, CP; Fleckenstein, LL; Mbah, AU; Nwonu, P; Okonkwo, PO; Umeh, RE, 1998)
"Ten male patients with onchocerciasis received six weekly infusions of suramin according to the WHO-recommended regimen."5.08Clinical pharmacokinetics of suramin in patients with onchocerciasis. ( Chijioke, CP; Fleckenstein, LL; Mbah, AU; Nwonu, P; Okonkwo, PO; Umeh, RE, 1998)
"This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine the ability of an adaptive control with feedback (ACF) dosing strategy to maintain suramin plasma concentrations within a preselected range; (3) to develop a population model of suramin pharmacokinetics; and (4) to identify preliminary evidence of antitumor activity."2.68Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ( Eisenberger, MA; Hemady, RK; Jacobs, SC; Jodrell, DI; Lowitt, MH; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1995)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wise, E1
Easom, N1
Watson, J1
Bailey, R1
Brown, M1
Eisenberger, MA1
Sinibaldi, VJ1
Reyno, LM1
Sridhara, R1
Jodrell, DI1
Zuhowski, EG1
Tkaczuk, KH1
Lowitt, MH1
Hemady, RK1
Jacobs, SC1
Chijioke, CP1
Umeh, RE1
Mbah, AU1
Nwonu, P1
Fleckenstein, LL1
Okonkwo, PO1
La Rocca, RV1
Meer, J1
Gilliatt, RW1
Stein, CA1
Cassidy, J1
Myers, CE1
Dalakas, MC1

Trials

2 trials available for suramin and Dysesthesia

ArticleYear
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adaptation, Physiological; Aged; Anorexia; Bayes Theorem; Cohort Studies; Drug Monitoring; Drug Resi

1995
Clinical pharmacokinetics of suramin in patients with onchocerciasis.
    European journal of clinical pharmacology, 1998, Volume: 54, Issue:3

    Topics: Adult; Animals; Antinematodal Agents; Exanthema; Foot; Humans; Hypopigmentation; Male; Metabolic Cle

1998

Other Studies

2 other studies available for suramin and Dysesthesia

ArticleYear
Lesson of the month: a psychiatric diagnosis overturned by a blood film.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:3

    Topics: Antibodies, Protozoan; Cerebrospinal Fluid; Diagnosis, Differential; Female; Humans; Melarsoprol; Me

2012
Suramin-induced polyneuropathy.
    Neurology, 1990, Volume: 40, Issue:6

    Topics: Adult; Cerebrospinal Fluid Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Neural Conduction

1990